| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 18 | 2023 | 80 | 4.640 |
Why?
|
| Crohn Disease | 9 | 2023 | 37 | 1.950 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2023 | 124 | 1.780 |
Why?
|
| Colitis, Ulcerative | 9 | 2022 | 57 | 1.630 |
Why?
|
| Intestinal Mucosa | 14 | 2019 | 157 | 1.390 |
Why?
|
| Diet | 6 | 2019 | 178 | 1.200 |
Why?
|
| Colon | 10 | 2019 | 110 | 1.100 |
Why?
|
| Dietary Carbohydrates | 3 | 2020 | 11 | 1.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2019 | 164 | 1.040 |
Why?
|
| Gastrointestinal Tract | 6 | 2018 | 41 | 1.020 |
Why?
|
| Particulate Matter | 3 | 2018 | 15 | 1.000 |
Why?
|
| Microbiota | 9 | 2023 | 65 | 0.920 |
Why?
|
| Humans | 54 | 2023 | 22823 | 0.780 |
Why?
|
| Metagenome | 4 | 2015 | 15 | 0.750 |
Why?
|
| Adiposity | 1 | 2021 | 42 | 0.700 |
Why?
|
| Diverticulitis | 1 | 2021 | 6 | 0.700 |
Why?
|
| Adipose Tissue | 1 | 2021 | 73 | 0.680 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 111 | 0.650 |
Why?
|
| Adult | 24 | 2023 | 6896 | 0.640 |
Why?
|
| Intestines | 4 | 2017 | 77 | 0.630 |
Why?
|
| Colitis, Collagenous | 1 | 2019 | 1 | 0.600 |
Why?
|
| Inhalation Exposure | 2 | 2018 | 5 | 0.590 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2017 | 31 | 0.590 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2018 | 3 | 0.590 |
Why?
|
| Female | 30 | 2023 | 12904 | 0.590 |
Why?
|
| Middle Aged | 23 | 2023 | 7873 | 0.570 |
Why?
|
| RNA, Ribosomal, 16S | 4 | 2017 | 39 | 0.570 |
Why?
|
| Air Pollutants | 1 | 2018 | 10 | 0.570 |
Why?
|
| Bacteria | 6 | 2017 | 61 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 83 | 0.550 |
Why?
|
| Male | 30 | 2021 | 12400 | 0.550 |
Why?
|
| Complementary Therapies | 1 | 2017 | 7 | 0.540 |
Why?
|
| ABO Blood-Group System | 1 | 2017 | 4 | 0.540 |
Why?
|
| HIV Infections | 4 | 2018 | 430 | 0.520 |
Why?
|
| Methane | 1 | 2016 | 2 | 0.500 |
Why?
|
| Diverticulum | 1 | 2016 | 3 | 0.500 |
Why?
|
| Ethanol | 3 | 2015 | 82 | 0.500 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2014 | 67 | 0.480 |
Why?
|
| Feces | 10 | 2019 | 80 | 0.460 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 219 | 0.450 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 3 | 0.450 |
Why?
|
| Hepatitis B | 1 | 2014 | 12 | 0.440 |
Why?
|
| Vaccination | 1 | 2014 | 26 | 0.440 |
Why?
|
| Dietary Proteins | 3 | 2017 | 26 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 97 | 0.410 |
Why?
|
| Gastrointestinal Transit | 1 | 2012 | 12 | 0.390 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 5 | 0.380 |
Why?
|
| Intestine, Small | 1 | 2012 | 30 | 0.380 |
Why?
|
| Oxidants | 2 | 2011 | 27 | 0.360 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 48 | 0.360 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 9 | 0.360 |
Why?
|
| Dysbiosis | 4 | 2015 | 36 | 0.360 |
Why?
|
| Alcoholism | 1 | 2012 | 64 | 0.350 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 46 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 390 | 0.320 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2009 | 6 | 0.310 |
Why?
|
| Dietary Fiber | 3 | 2020 | 25 | 0.310 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 14 | 0.310 |
Why?
|
| Endotoxemia | 1 | 2009 | 19 | 0.310 |
Why?
|
| Aged | 13 | 2019 | 7412 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 4 | 2017 | 111 | 0.290 |
Why?
|
| Animals | 9 | 2019 | 3255 | 0.280 |
Why?
|
| Starch | 2 | 2019 | 9 | 0.280 |
Why?
|
| Inflammation | 4 | 2018 | 226 | 0.280 |
Why?
|
| Quality of Life | 4 | 2020 | 559 | 0.270 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 13 | 0.250 |
Why?
|
| Serum Albumin | 1 | 2006 | 21 | 0.250 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 15 | 0.250 |
Why?
|
| Colon, Sigmoid | 2 | 2017 | 11 | 0.250 |
Why?
|
| Biopsy | 6 | 2018 | 186 | 0.240 |
Why?
|
| Mice | 5 | 2018 | 1228 | 0.240 |
Why?
|
| Air Pollution | 2 | 2018 | 13 | 0.230 |
Why?
|
| Metabolome | 2 | 2015 | 9 | 0.220 |
Why?
|
| Volatile Organic Compounds | 2 | 2015 | 8 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 363 | 0.210 |
Why?
|
| Case-Control Studies | 5 | 2017 | 481 | 0.210 |
Why?
|
| Logistic Models | 2 | 2016 | 350 | 0.200 |
Why?
|
| Remission Induction | 3 | 2020 | 89 | 0.200 |
Why?
|
| Reactive Oxygen Species | 3 | 2011 | 98 | 0.190 |
Why?
|
| Retrospective Studies | 3 | 2016 | 2976 | 0.190 |
Why?
|
| alpha-Synuclein | 2 | 2015 | 103 | 0.190 |
Why?
|
| Gastrointestinal Agents | 1 | 2002 | 9 | 0.180 |
Why?
|
| Veterans | 1 | 2023 | 87 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2021 | 8 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 129 | 0.180 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 108 | 0.180 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 86 | 0.170 |
Why?
|
| Young Adult | 5 | 2019 | 1647 | 0.170 |
Why?
|
| Celiac Disease | 2 | 2016 | 7 | 0.170 |
Why?
|
| Dietary Fats | 2 | 2017 | 37 | 0.170 |
Why?
|
| Adolescent | 3 | 2015 | 1874 | 0.170 |
Why?
|
| Phylogeny | 2 | 2017 | 44 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 203 | 0.160 |
Why?
|
| Constipation | 2 | 2017 | 16 | 0.160 |
Why?
|
| Antioxidants | 3 | 2006 | 54 | 0.150 |
Why?
|
| Firmicutes | 1 | 2019 | 5 | 0.150 |
Why?
|
| Butyrates | 1 | 2019 | 12 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2019 | 24 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 53 | 0.150 |
Why?
|
| Fatty Acids | 2 | 2019 | 33 | 0.150 |
Why?
|
| Interferon Type I | 1 | 2018 | 9 | 0.140 |
Why?
|
| Prevalence | 2 | 2022 | 375 | 0.140 |
Why?
|
| Hospitalization | 2 | 2023 | 285 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2018 | 19 | 0.140 |
Why?
|
| Wound Healing | 1 | 2019 | 107 | 0.140 |
Why?
|
| Ileum | 3 | 2017 | 16 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 104 | 0.140 |
Why?
|
| Micronutrients | 1 | 2017 | 1 | 0.140 |
Why?
|
| Adaptation, Psychological | 2 | 2021 | 165 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 9 | 0.140 |
Why?
|
| Food Additives | 1 | 2017 | 6 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 11 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 258 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 35 | 0.140 |
Why?
|
| Discriminant Analysis | 1 | 2017 | 9 | 0.140 |
Why?
|
| NF-kappa B | 2 | 2011 | 99 | 0.130 |
Why?
|
| Kupffer Cells | 1 | 2017 | 2 | 0.130 |
Why?
|
| Defecation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2017 | 10 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2017 | 59 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 27 | 0.130 |
Why?
|
| Candida | 1 | 2017 | 16 | 0.130 |
Why?
|
| Microspheres | 1 | 2017 | 24 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 56 | 0.130 |
Why?
|
| Prebiotics | 1 | 2017 | 18 | 0.130 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2017 | 1 | 0.130 |
Why?
|
| Parkinson Disease | 2 | 2015 | 591 | 0.130 |
Why?
|
| Biodiversity | 1 | 2017 | 31 | 0.130 |
Why?
|
| Multiple System Atrophy | 1 | 2017 | 26 | 0.130 |
Why?
|
| Risk Factors | 4 | 2021 | 1966 | 0.130 |
Why?
|
| Breath Tests | 1 | 2016 | 10 | 0.120 |
Why?
|
| Biomarkers | 3 | 2014 | 477 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 231 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 759 | 0.120 |
Why?
|
| Zonula Occludens-1 Protein | 2 | 2017 | 10 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 132 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 40 | 0.120 |
Why?
|
| Chicago | 2 | 2017 | 811 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 21 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2016 | 70 | 0.120 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 52 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 105 | 0.110 |
Why?
|
| Permeability | 3 | 2014 | 90 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 2015 | 11 | 0.110 |
Why?
|
| Caudovirales | 1 | 2015 | 2 | 0.110 |
Why?
|
| Microviridae | 1 | 2015 | 2 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 7 | 0.110 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 5 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hypertension | 1 | 2016 | 163 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2016 | 186 | 0.110 |
Why?
|
| Particle Size | 2 | 2011 | 35 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2014 | 53 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 5 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 63 | 0.110 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2011 | 70 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 172 | 0.110 |
Why?
|
| Diarrhea | 1 | 2014 | 31 | 0.110 |
Why?
|
| Age Factors | 1 | 2016 | 633 | 0.110 |
Why?
|
| Mastectomy | 1 | 2014 | 34 | 0.110 |
Why?
|
| Photoperiod | 1 | 2014 | 28 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 100 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 153 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2014 | 82 | 0.110 |
Why?
|
| Solid Phase Microextraction | 1 | 2013 | 3 | 0.100 |
Why?
|
| Mental Competency | 1 | 2013 | 9 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 122 | 0.100 |
Why?
|
| Artifacts | 1 | 2013 | 29 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2013 | 40 | 0.100 |
Why?
|
| Cytokines | 3 | 2017 | 202 | 0.100 |
Why?
|
| Patient Participation | 1 | 2013 | 43 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 438 | 0.100 |
Why?
|
| Caco-2 Cells | 2 | 2011 | 42 | 0.100 |
Why?
|
| Fatty Acids, Volatile | 3 | 2019 | 26 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 198 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 572 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2011 | 81 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 20 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2022 | 364 | 0.090 |
Why?
|
| Child | 1 | 2015 | 1153 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 213 | 0.090 |
Why?
|
| Enteric Nervous System | 1 | 2011 | 5 | 0.090 |
Why?
|
| District of Columbia | 1 | 2011 | 2 | 0.090 |
Why?
|
| Occludin | 1 | 2011 | 8 | 0.090 |
Why?
|
| Inpatients | 1 | 2012 | 113 | 0.090 |
Why?
|
| Electric Impedance | 1 | 2011 | 23 | 0.090 |
Why?
|
| Tight Junctions | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 33 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 23 | 0.090 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mitochondria | 1 | 2011 | 52 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2011 | 20 | 0.090 |
Why?
|
| Food Hypersensitivity | 2 | 2008 | 40 | 0.080 |
Why?
|
| Pneumonia | 1 | 2011 | 61 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2011 | 146 | 0.080 |
Why?
|
| Peptide Mapping | 1 | 2009 | 4 | 0.080 |
Why?
|
| Intestinal Absorption | 1 | 2009 | 30 | 0.080 |
Why?
|
| Glucose | 1 | 2009 | 43 | 0.080 |
Why?
|
| Neurons | 1 | 2011 | 273 | 0.070 |
Why?
|
| Antigens | 1 | 2008 | 9 | 0.070 |
Why?
|
| Immune System | 1 | 2008 | 11 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 314 | 0.070 |
Why?
|
| Tyrosine | 2 | 2011 | 22 | 0.070 |
Why?
|
| Rats | 1 | 2009 | 623 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2007 | 4 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 14 | 0.070 |
Why?
|
| Pouchitis | 1 | 2007 | 2 | 0.070 |
Why?
|
| Colonic Pouches | 1 | 2007 | 2 | 0.070 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2007 | 4 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 37 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2006 | 7 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2006 | 10 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 43 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 3717 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2006 | 36 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2006 | 47 | 0.060 |
Why?
|
| Health Status Disparities | 2 | 2017 | 63 | 0.060 |
Why?
|
| Esophagitis | 1 | 2003 | 6 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 7 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2003 | 35 | 0.050 |
Why?
|
| Microtubules | 1 | 2003 | 26 | 0.050 |
Why?
|
| Colonic Diseases, Functional | 1 | 2003 | 3 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 26 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2003 | 33 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 268 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 12 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2003 | 72 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 26 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 392 | 0.050 |
Why?
|
| Quinolones | 1 | 2002 | 11 | 0.050 |
Why?
|
| Alanine | 1 | 2002 | 12 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2002 | 27 | 0.050 |
Why?
|
| Digestive System | 1 | 2002 | 14 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 84 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2002 | 20 | 0.050 |
Why?
|
| Neutrophils | 1 | 2002 | 89 | 0.050 |
Why?
|
| Uncertainty | 1 | 2021 | 10 | 0.040 |
Why?
|
| Proctitis | 1 | 2001 | 3 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2002 | 83 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2001 | 28 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 164 | 0.040 |
Why?
|
| Vitamin E | 1 | 2001 | 37 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2001 | 27 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1258 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 201 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 326 | 0.040 |
Why?
|
| Meat | 1 | 2020 | 1 | 0.040 |
Why?
|
| Food, Organic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2020 | 11 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 21 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 311 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 117 | 0.040 |
Why?
|
| Solanum tuberosum | 1 | 2019 | 2 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 362 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 243 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 235 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 51 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 143 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2017 | 4 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 39 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 70 | 0.030 |
Why?
|
| Fermentation | 1 | 2017 | 13 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 47 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 1412 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 33 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 276 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 373 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Birth Weight | 1 | 2016 | 38 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 82 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 73 | 0.030 |
Why?
|
| Employment | 1 | 2016 | 38 | 0.030 |
Why?
|
| Income | 1 | 2016 | 63 | 0.030 |
Why?
|
| Protein Folding | 1 | 2015 | 16 | 0.030 |
Why?
|
| Alkanes | 1 | 2015 | 2 | 0.030 |
Why?
|
| Terpenes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Sulfides | 1 | 2015 | 8 | 0.030 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 5 | 0.030 |
Why?
|
| Disulfides | 1 | 2015 | 9 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 5 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 255 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 209 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 171 | 0.030 |
Why?
|
| Metabolomics | 1 | 2014 | 6 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 10 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 2014 | 18 | 0.030 |
Why?
|
| Lactobacillus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 5 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 12 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 478 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 534 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 10 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Light | 1 | 2014 | 55 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 439 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 295 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 591 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1047 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 1487 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 174 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 517 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 206 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 1412 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2011 | 4 | 0.020 |
Why?
|
| Fibrin | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cities | 1 | 2011 | 12 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 94 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2011 | 101 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 368 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 227 | 0.020 |
Why?
|
| Lung | 1 | 2011 | 138 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1019 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Biofilms | 1 | 2007 | 13 | 0.020 |
Why?
|
| Herbal Medicine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 169 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 101 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 323 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2006 | 44 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 190 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 546 | 0.010 |
Why?
|
| Asthma | 1 | 2006 | 152 | 0.010 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
|
| Budesonide | 1 | 2003 | 3 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 4 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2003 | 9 | 0.010 |
Why?
|
| Azathioprine | 1 | 2003 | 6 | 0.010 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 6 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 2003 | 11 | 0.010 |
Why?
|
| Esophageal Perforation | 1 | 2003 | 8 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 13 | 0.010 |
Why?
|
| Proton Pumps | 1 | 2003 | 12 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 30 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2003 | 27 | 0.010 |
Why?
|
| Catheterization | 1 | 2003 | 40 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 7 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2003 | 8 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 37 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 35 | 0.010 |
Why?
|
| Eosinophils | 1 | 2003 | 35 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 64 | 0.010 |
Why?
|
| Free Radicals | 1 | 2003 | 7 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 251 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2003 | 19 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 15 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 51 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 114 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 35 | 0.010 |
Why?
|
| Esophagus | 1 | 2003 | 53 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 61 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 122 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 309 | 0.010 |
Why?
|
| Gastric Acid | 1 | 2002 | 9 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 123 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2002 | 32 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 162 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 162 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 1319 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 2934 | 0.010 |
Why?
|